Samsung Biologics unveils $920 million manufacturing deals for Pfizer
SEOUL (Reuters) – South Korea’s Samsung Biologics announced on Tuesday two deals with Pfizer worth around a combined 1.2 trillion won ($921.38 million) to manufacture products for the U.S. pharmaceutical giant. The latest deals will see the biotech division of the Samsung Group produce biosimilar products ranging from oncology and inflammation to immunotherapy in the…
